CVS says GLP-1s save money when priced below $350 per month
CVS•CVS Health said health plan sponsors could break even on GLP-1 drugs priced below $350 per month. Its analysis found sponsors saved $9,400 per person on medical bills over three years but spent $13,300 more on prescriptions, adding $3,900 in costs.
1. Three-year cost analysis
CVS Health analyzed Aetna claims for patients taking GLP-1 drugs for obesity, diabetes and other conditions, comparing them with similar patients not taking the drugs. The analysis covered patients starting treatment from 2023 to 2025 and found that current drug prices outweighed lower medical costs.
2. Fewer hospitalizations
CVS said GLP-1 use was associated with 10% to 12% fewer emergency room visits in the first and second years. Among 4,000 people still taking the drugs after three years, hospitalizations fell by 34% to 42%.
3. Coverage and pricing
Employers and other health plan sponsors pay $617 to $766 per month for the drugs, according to a 2025 study cited in the article. CVS Chief Medical Officer Amy Compton-Phillips said lower direct-to-consumer prices suggest drugmakers could profit below $350 monthly while helping reduce overall health costs. She said savings may come sooner for higher-risk patients.
